LANTERNA announces SANTIS ̈Hybrid ̈ Pedicle Screw System successfully completes 510k testing


Lanterna Medical Technologies Lanterna Medical Technologies, a medical device company focused on developing innovative, intuitive and cost effective solutions for spine disease, announced today, that their SANTISTM  ̈HYBRID ̈ PEDICLE SCREW SYSTEM successfully completed all the mechanical tests that are required by the FDA for a 510K registration.

Mr. Horace Hale, President of Lanterna said: “We are extremely pleased and excited to have completed this major milestone with such exemplary results. It is a matter of deep pride for us here at LANTERNA, that our products not only meet but surpass all of the tests which are imposed by the regulatory authorities to whom we must report, and the SANTISTM  ̈HYBRID ̈ PEDICLE SCREW SYSTEM performed above every expectation. Our sense of accomplishment is even more enhanced by the fact that these test were performed at an independent testing facility with an impeccable record of quality and professionalism ̈. LANTERNA has now begun the process of submission to the FDA for permission to market the SANTISTM  ̈HYBRID ̈  PEDICLE SCREW SYSTEM in the USA. This process is estimated to be completed in 90 days. This event marks a major accomplishment in LANTERNA’S campaign to bring their innovative solutions to their partners worldwide.



LANTERNA cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause LANTERNA’S results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the risk that LANTERNA’S revenue or earnings projections may turn out to be inaccurate because of the preliminary nature of the forecasts; the risk of further adjustment, or unanticipated difficulty in selling products or generating expected profitability; and other risks and uncertainties more fully described in LANTERNA’S press releases. LANTERNA assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made. Postfach 231, Rorschacherstr. 294, 9016 St. Gallen, Switzerland. T:+41 71 280 0930; F:+41 71 370 0522.